Biomimetic Proteoglycans for Intervertebral Disc (IVD) Regeneration
Neha Chopra1, James Melrose2,3,4, Zi Gu5,6,7
1Spine Service & Spine Labs, St George & Sutherland School of Clinical Medicine, Faculty of Health and Medicine, University of New South Wales, Kogarah, NSW 2217, Australia.
Biomimetics (Basel, Switzerland)
|December 27, 2024
Summary
Intervertebral disc degeneration (IVDD) causes low back pain. Engineered proteoglycans offer a cell-free approach to restore disc function and improve patient outcomes.
Area of Science:
- Biomaterials Science
- Orthopedics
- Regenerative Medicine
Background:
- Intervertebral disc degeneration (IVDD) is a leading cause of low back pain, impacting quality of life and incurring significant socioeconomic costs.
- Reduced cell numbers and viability in aging intervertebral discs (IVDs) hinder cell-based regenerative therapies.
- Restoring proteoglycan levels, crucial for IVD function, via non-cellular methods is a promising therapeutic strategy.
Purpose of the Study:
- To provide a comprehensive overview of orthobiological strategies utilizing engineered proteoglycans for treating IVD degeneration.
- To explore the potential of biomimetic proteoglycans (PGs) as a therapeutic intervention for IVDD.
- To highlight advancements in engineered PGs for enhanced therapeutic efficacy in IVD repair.
Main Methods:
- Review of existing literature on proteoglycans, biomimetic polymers, and their application in cartilage and IVD repair.
- Discussion of the properties of biomimetic PGs, including water imbibition and resistance to degradation.
- Exploration of methods for chemically editing biomimetic PGs to incorporate bioactive modules and drug delivery capabilities.
Main Results:
- Biomimetic PGs demonstrate superior water imbibing properties and enhanced resistance to proteolytic degradation compared to native aggrecan.
- Engineered biomimetic PGs can serve as effective delivery vehicles for drugs and growth factors.
- These engineered PGs have shown potential in strengthening cartilage and promoting biological repair.
Conclusions:
- Engineered proteoglycans represent a promising cell-free orthobiological strategy for addressing intervertebral disc degeneration.
- Biomimetic PGs offer a viable approach to replenish proteoglycan levels and restore mechanical properties of degenerate IVDs.
- Further development of engineered proteoglycans holds significant potential for novel therapeutic interventions and improved patient outcomes in low back pain management.
More Related Videos
Related Concept Videos
01:27Degenerative Disc Disease I: Introduction
29
Degenerative disc disease is a chronic condition in which intervertebral discs gradually lose structure and function. It is not infectious or autoimmune; rather, it results from age-related biochemical and mechanical changes, influenced by genetic, metabolic, and environmental factors.Structure and Function of DiscsThe spine contains 23 intervertebral discs that absorb load, distribute forces, maintain spacing, and allow flexibility. Each disc consists of a nucleus pulposus, a gel-like core...
29
01:23Degenerative Disc Disease ll: Pathophysiology
34
The symptoms of degenerative disc disease arise from a combination of mechanical compression, vascular compromise, and biochemical inflammation, which together disrupt nerve function and produce pain.Mechanical CompressionDisc degeneration reduces height and elasticity, predisposing to herniation of the nucleus pulposus, a major cause of radicular pain. Herniations may be protrusion (bulging with intact annulus), extrusion (nucleus extends beyond disc but remains connected), or sequestration...
34